Moderna ($MRNA) preliminary FY2025: revenue ≈ $1.9B; GAAP operating expenses $5.0–$5.2B; cash, cash…
Filed with the SEC on · Summarized by InvestorsBot
Moderna ($MRNA) preliminary FY2025: revenue ≈ $1.9B; GAAP operating expenses $5.0–$5.2B; cash, cash equivalents & marketable securities ≈ $8.1B. Press release dated Jan 12, 2026 at 44th J.P. Morgan Healthcare Conference. Unaudited/preliminary. 📄📊 #Moderna #Biotech
Preliminary gap: FY2025 revenue ~$1.9B vs. GAAP op expenses $5.0–$5.2B → implied operating shortfall ≈ $3.1–$3.3B (unaudited). Cash & securities ≈ $8.1B as of 12/31/25. Audit ongoing; figures may change. 💸🧾 $MRNA #Earnings #Investing
Disclosure reminder: numbers released Jan 12, 2026 at JPM are preliminary and unaudited; the year‑end 2025 audit is ongoing and could alter results. Investors should await audited financial statements. 🕒 $MRNA #JPM2026 #Moderna